Geisinger Clinic
Multiple Locations, Pennsylvania, 00000, United States
NCT Number: NCT05284513
Diagnosis rates of familial hypercholesterolemia (FH) are low in the United States, despite multiple guidelines and recommendations for screening and treatment of high cholesterol, to prevent heart attacks in those affected. Using a stepped-wedge design, the investigators plan to utilize tools from implementation science to improve uptake, acceptability, and sustainability of FH diagnostic programs in primary care settings. If successful, this study will provide tools generalizable to other health care systems to improve FH diagnosis rates.
Interested in participating?
Request Info26 year and older
All sexes
Interventional
Not applicable
Multiple Locations, Pennsylvania, 00000, United States
Familial hypercholesterolemia (FH) is a common genetic disorder (prevalence 1 in 250) that requires lifelong sustained medical care. Evidence-based guidelines for screening and treatment for FH exist. These include universal screening of children ages 9-11, of adolescents ages 18-20, and of adults ages 40 and above; approved diagnostic tools including lipid panels and genetic testing; and recommendations for initiation of lipid lowering medication. FH diagnosis is currently made too late in life, often after a premature heart attack has occurred creating a care gap that results in excess cardiovascular morbidity and mortality. Diagnosing FH in the primary care setting would optimize treatment for individuals with FH and close this care gap. Utilizing tools from implementation science and human centered design, and by considering uptake, acceptability, and sustainability of programs related to FH care should improve earlier diagnosis. Implementation strategies that include insights from patients, clinicians, and healthcare systems are necessary. The long-term goal is to create an effective FH diagnosis program that is practical and sustainable in the real-world setting. The main objective of this project is to determine the uptake of an FH diagnosis program integrated into primary care practices to promote early identification of adult and pediatric patients that is generalizable to other healthcare settings. The research question is, does using a multi-level implementation strategy package, designed to address the specific needs of patients, clinicians, and healthcare systems, improve the diagnosis and activation of care management for individuals with FH. The specific aims are to: 1) to design a clinical trial to assess multi-level implementation strategies for improving FH diagnosis in an integrated health system, 2) compare FH diagnosis rates among primary care clinicians who receive the implementation strategy package versus those who do not, 3) to measure implementation success of an organized FH diagnosis program, and 4) to explore patient-related service and health outcomes related to an FH diagnosis program.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Uptake of screening, diagnosis, and initiation of care management for FH
EHR tools to order labs, record results, and document FH care
Education regarding guidelines for identification and treatment of FH
Continuing medical education (CME) material for FH that is presented to
Notify patients simultaneously with clinicians about the need for screening
Clinical lipid champions
Provide aggregate level feedback to clinics on diagnosing FH
Develop the timeline for the stepped-wedge rollout to primary care
Time frame: Up to 45 months
FH diagnosis rate, is achieving both the scheduling of a clinic visit and evidence the clinician, at that visit, has completed evidence-based FH diagnostic evaluation, defined as completing one of: using the FH clinic note to document care, adding FH diagnosis on the problem list, using the FH smart-set (or ordered a genetic test for FH), making a referral to the lipid clinic, or starting a statin for an evidence-based indication
Time frame: Month 9, 12, 18, 24, 30, 36, 42
Clinician and patient satisfaction and self-efficacy with the FH diagnosis program
Time frame: Up to 45 months
Time to FH screen, time to diagnostic evaluation, time to statin initiation
Time frame: Up to 45 months
Initiation of lipid lowering medication by healthcare clinician
Time frame: Up to 45 months
Order of a lipid panel
Time frame: Month 9, 12, 18, 24, 30, 36, 42
Order of a genetic test for FH
Time frame: Up to 45 months
Clinician adds diagnosis of FH to the patients problem list in the electronic health record
Time frame: Month 9, 12, 18, 24, 30, 36, 42
Clinician uses and completes all field of the FH smartset
Time frame: Up to 45 months
Clinician adheres to and acts on recommendation in the Best Practice Alert
Time frame: Up to 45 months
Clinician completes the FH clinic note
Time frame: Up to 45 months
Documentation of adaptations to the FH diagnosis program
Time frame: Up to 45 months
Cost to implement the implementation strategy package
Time frame: Up to 45 months
Return of genetic result to patient (if ordered and patient undergoes testing)
Time frame: Up to 45 months
Reduction in lipid level from baseline to end of the study period
Time frame: Up to 45 months
Patient side effects to medications
Geisinger Clinic
Other
Acronym: CARE-FH
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05746247
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyslipidemias
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT05750667
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyslipidemias
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT04798430
Cardiovascular Disease With Mention of Arteriosclerosis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Evanston, Illinois, United States
View Trial DetailsNCT04929457
Arterial Occlusive Diseases, Arteriosclerosis
Stockholm, Sweden
View Trial Details